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Introduction 
With an estimated 417,000 new cases in 2014 in Europe, prostate cancer (PCa) remains the 
most often diagnosed gender-specific carcinoma for men [1]. The current routine of 
diagnosing PCa results in a significant number of unnecessary biopsies and treatments of non-
cancerous, benign prostate conditions and non-aggressive cancers, leading to severe negative 
effects for both men and healthcare systems [2,3]. 
Next to well-studied pathways such as androgen receptor (AR) and PI3K/AKT, cyclic AMP 
(cAMP) has been shown to play a role in the development and progression of PCa [4]. The 
metabolism of cAMP in cells is complex and tailored by spatial and signalling cross-talk 
considerations involving both a large family of adenylyl cyclases responsible for its synthesis, 
and a large family of cyclic nucleotide phosphodiesterases (PDEs) responsible for its 
degradation [5]. It is now well recognized that when particular cAMP degrading PDEs are 
recruited to specific signalling complexes they create and control cAMP gradients around 
them, allowing spatially compartmentalised and time-dependent regulation of localized cAMP 
signalling [6,7]. Protein domains involved in subcellular localization as well as independent 
regulatory mechanisms play a pivotal role in these processes, granting PDE isoforms the 
ability to fulfil functionally independent and unique roles in the cell [6,8]. Thus changes in the 
expression of distinct PDE isoforms can be expected to reprogram downstream signalling 
pathways during disease development and progression, providing potential targets for novel 
markers and therapeutic interventions [6]. Indeed, cAMP-degrading PDEs have been 
associated with several diseases in recent years, including stroke, acrodysostosis and COPD 
[9–14], and more recently, expression of a specific PDE4D isoform (PDE4D7) has been 
related to prostate cancer [15,16]. 
The PDE4D7 transcript hosts the open reading frame for a long PDE4D isoform that contains 
both the UCR1 and UCR2 regulatory domains [17]. These protein domains are common to all 
long PDE4D isoforms with UCR1 being phosphorylated by PKA (cAMP dependent protein 
kinase A), when cAMP levels within the cell are elevated, leading to enzyme activation 
[18,19]. Indeed, activation of long PDE4 isoforms, such as PDE4D7, by PKA provides a 
fundamental part of the cellular desensitization process to cAMP [6]. Long PDE4 isoforms 
can also be dynamically regulated through phosphorylation by other key signalling system 
kinases, namely, by ERK [20], MK2 [21], Cdk5 [22] and AMPK [23]. Additionally, PDE4D7 
has been shown [15] to be specifically targeted to the sub-plasma membrane compartment in 
prostate cancer cells where it regulates local cAMP levels that are linked to cell proliferation 
[15].  
2 
 
Abstract 
Phosphodiesterase 4D7 was recently shown to be specifically over-expressed in localized 
prostate cancer, raising the question as to which regulatory mechanisms are involved and 
whether other isoforms of this gene family (PDE4D) are affected under the same conditions. 
We investigated PDE4D isoform composition in prostatic tissues using a total of seven 
independent expression datasets and also included data on DNA methylation, copy number 
and AR and ERG binding in PDE4D promoters to gain insight into their effect on PDE4D 
transcription. 
We show that expression of PDE4D isoforms is consistently altered in primary human 
prostate cancer compared to benign tissue, with PDE4D7 being up-regulated while PDE4D5 
and PDE4D9 are down-regulated. Disease progression is marked by an overall down-
regulation of long PDE4D isoforms, while short isoforms (PDE4D1/2) appear to be relatively 
unaffected. While these alterations seem to be independent of copy number alterations in the 
PDE4D locus and driven by AR and ERG binding, we also observed increased DNA 
methylation in the promoter region of PDE4D5, indicating a long lasting alteration of the 
isoform composition in prostate cancer tissues. 
We propose two independent metrics that may serve as diagnostic and prognostic markers for 
prostate disease: !"#4"7 − !"#4"5  provides an effective means for distinguishing PCa 
from normal adjacent prostate, whereas !"#4"1/2 − (!"#4"5 + !"#4"7 + !"#4"9) 
offers strong prognostic potential to detect aggressive forms of PCa and is associated with 
metastasis free survival. Overall, our findings highlight the relevance of PDE4D as prostate 
cancer biomarker and potential drug target. 
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We have previously shown that PDE4D7 is specifically overexpressed in both androgen 
sensitive PCa cells and in samples from patients with early androgen sensitive prostate disease 
[15,16]. However, in marked contrast to this, once PCa cells become androgen 
insensitive/independent (castration resistant), expression of PDE4D7 declines [15,16]. 
Here, we show that PDE4D isoform composition is altered in localized prostate cancer and 
that it can be used both as a diagnostic as well as a prognostic biomarker. In conjunction with 
our previous studies, we see that the long transcript isoform PDE4D7 is up-regulated in 
localized disease compared to normal adjacent prostate (NAP), while its expression 
diminishes with tumour progression. In contrast to PDE4D7, two other long isoforms, 
PDE4D5 and PDE4D9, do not undergo an initial up-regulation in primary PCa and instead are 
increasingly down-regulated during disease progression. Moreover, we suggest that that this 
change in isoform composition may be influenced by the DNA methylation of specific 
regulatory elements of the PDE4D locus. These findings highlight the potential of using 
condition-specific mRNA isoforms of the PDE4D gene as biomarkers and potential novel 
therapy targets to restore benign conditions. 
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Results 
 
The long isoforms PDE4D5 and PDE4D9 are significantly down-regulated in primary 
prostate cancer, independent of copy number alterations in the PDE4D gene locus 
 
After previously identifying PDE4D7 as a novel biomarker candidate [16], we wanted to 
investigate the behaviour of other PDE4D transcript isoforms in PCa development and 
progression. Therefore, we focused on the nine major human PDE4D isoforms described in 
RefSeq and conducted a meta-analysis of six publicly available patient cohorts. Our analysis 
revealed that many PDE4D isoforms are seemingly expressed at stable levels when using 
Exon Arrays, whereas only PDE4D1/2, PDE4D5, PDE4D7, and PDE4D9 were detectable at 
higher levels in our independent qRT-PCR cohort of prostate tissues (see Figure 1 and 
Supplementary Figures 1-5). These findings were supported by the TCGA PRAD RNA-seq 
cohort, which mostly agreed with RT-PCR results, despite few outlier samples showing 
expression of other isoforms (Supplementary Figure 6). Based on these findings, we focused 
on the above mentioned PDE4D isoforms, as they showed consistent expression profiles in all 
used cohorts. Using these criteria, we found that both PDE4D5 and PDE4D9 are significantly 
down-regulated in primary localized PCa when compared to benign samples. Moreover, 
patient samples derived from castration-resistant prostate cancer (CRPC) showed further 
down-regulation of both isoforms, in line with our previous findings for PDE4D7 [16].  
Likewise, PCa metastases samples followed this trend, but often displayed higher variance in 
PDE4D isoform expression, as can be expected given their very heterogeneous genomic 
background [24]. 
Since, partial or complete deletions of one or both alleles of the PDE4D gene have been 
reported previously in prostate cancer [25–27] we utilized TCGA SNP array data of matching 
patient samples to assess the potential impact of deletions occurring in PDE4D on isoform 
expression. Although we did observe a significant reduction in gene expression upon loss of 
genetic material, both isoforms were also expressed at significantly lower levels in PCa 
samples that did not harbour a deletion when comparing to matching normal samples (Figure 
2). 
 
Androgen receptor and ERG are implicated in transcriptional regulation of PDE4D 
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Our previous work suggested an association between PDE4D7 expression and the presence of 
the TMPRSS2-ERG fusion gene [16]. We therefore set out here to investigate whether there 
was any comparable ERG involvement in the expression of PDE4D5, PDE4D7 and PDE4D9 
in prostate disease. In order to do this, we assigned localized PCa samples to one of two 
groups based on an unsupervised clustering by Partitioning Around Medoids of ERG 
expression values and used available ERG IHC information of the 'EMC' cohort to confirm 
the validity of this approach. Clustering based grouping showed good concordance with IHC 
results, assigning four additional samples (10.2%) to the ERG positive group (Supplementary 
Figure 7).  
Interestingly, while we were able to confirm PDE4D7 overexpression in ERG positive PCa 
samples, PDE4D1/2 and PDE4D9 seemed unaffected by ERG, whereas PDE4D5 expression 
was altered significantly in two out of five datasets, suggesting that any connection between 
PDE4D5 and ERG is weak at best (see Figure 3). Of note, the Erho dataset consistently 
showed significant changes for all isoforms, however, these likely do not reflect real events, 
as absolute log2 fold changes were small (|log2FC| < 1) except for PDE4D7 (data not shown). 
Therefore, ERG linkage discriminates between PDE4D7 and the grouping of PDE4D1/2, 
PDE4D5 and PDE4D9, where we see differences between these two groups in the change in 
their expression in prostate disease. 
To investigate androgen-dependence of PDE4D isoform expression, we incorporated a public 
dataset of LNCaP cells measured after being kept either in androgen stripped medium (using 
dextran-coated charcoal - DCC) or after addition of the synthetic androgen R1881 [28]. While 
PDE4D9 expression was not altered after treatment, both PDE4D5 and PDE4D7 showed 
significant differences in expression after R1881 addition (Figure 4). Specifically, PDE4D5 
expression appeared to be inhibited upon AR stimulation, while PDE4D7 was up-regulated in 
DCC by the synthetic androgen R1881 in LNCaP cells. 
Next, we made use of public ChIP-seq data from the VCaP PCa cell line [29] treated with 
R1881 in order to gather further evidence of AR involvement in PDE4D expression. In ChIP-
seq, DNA binding proteins and associated chromatin are cross-linked, followed by 
immunoprecipitation of a protein of interest and subsequent sequencing of the associated 
DNA fragments, allowing a genome-wide localisation of its DNA binding sites. Overall, we 
found 31 ChIP-seq peaks for AR in PDE4D, two of which were near the first exon of 
PDE4D7 (~2 kb and 3 kb upstream), while another was partially overlapping the first exon of 
PDE4D5 (see Supplementary Table 1). No peaks could be found in proximity to the PDE4D9 
transcription start site (TSS), as the closest upstream and downstream peaks found at an 
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approximate distance of 85.5 kb and 44.2 kb, respectively. Since VCaP harbours the 
TMPRSS2-ERG gene fusion and ChIP-seq data for ERG was available from the same source, 
we included it in our analysis and found 43 ERG peaks in the PDE4D gene locus, of which 
some were found to partially overlap the first exon of each of the long isoforms PDE4D5, 
PDE4D7 and PDE4D9 (see Figure 5 and Supplementary Table 2). Since the number of ChIP-
seq peaks located in PDE4D appears to be rather high, we were wondering whether binding of 
AR and/or ERG within the gene locus occurs more often as compared to other regions. For 
this reason, we counted the number of AR and ERG peaks in 21,209 RefSeq gene loci and 
used these counts to construct empirical cumulative distribution functions (ECDFs) for both 
transcription factors. These ECDFs model the background distribution of the counts for both 
AR and ERG across all genes and enable us to calculate in which percentile the peak counts 
for AR and ERG in PDE4D are falling. Surprisingly, both AR and ERG were among the top 
99.9% of all genes (99.953th and 99.995th percentiles, respectively), suggesting a very strong 
enrichment in AR and ERG binding within the PDE4D gene locus (see Supplementary Figure 
8a). However, since PDE4D is a comparably large gene and spans approximately 1.5 Mb of 
genomic space, we repeated this analysis using more than three million randomly sampled 
genomic regions of 1.5 Mb size across all major chromosomes. Again, we found that PDE4D 
was highly enriched in AR and ERG binding peaks (95.151th and 87.624th percentiles, 
respectively) compared to random genomic stretches of comparable size (Supplementary 
Figure 8b). As a whole, these data support the observed expression profiles and suggest an 
involvement of both AR and ERG in overall PDE4D isoform regulation. 
 
DNA methylation of defined regions in PDE4D is altered in prostate cancer 
 
To further study transcriptional regulation of the PDE4D locus, we obtained public data of 
DNA methylation in PCa patients from Gene Expression Omnibus (GEO) and TCGA and 
performed statistical analyses to identify hyper- and hypo-methylated regions in PCa as 
compared to normal adjacent prostate (NAP). The results of three different platforms 
determining DNA methylation patterns consistently detected hyper-methylated regions, 
indicating active silencing of several PDE4D promoters in PCa, involving the transcription 
start site (TSS) of a total of five PDE4D isoforms, namely the short PDE4D1/2 isoforms and 
the long PDE4D4, PDE4D5 and PDE4D8 isoforms (see Supplementary Figure 9). 
To estimate the impact of these differentially methylated regions (DMRs) on isoform 
expression, we used Affymetrix Human Exon Array samples obtained from the same patients 
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as the MeDIP-seq cohort [30,31] and calculated Spearman's correlation coefficient for each of 
the differentially methylated regions (DMRs) and the associated PDE4D isoform. Of the five 
TSS involved, PDE4D5 showed the strongest negative association (r = -0.571, 
Supplementary Table 3), while the four DMRs near the PDE4D4 TSS showed varying 
agreement between methylation and expression measurements, ranging from r = -0.215 to r = 
-0.394. These results follow the expected behaviour, as increased DNA methylation impedes 
transcription [32]. Since the PDE4D1 and PDE4D2 expression could not be independently 
measured with the Exon Arrays, a negative correlation (r = -0.517) was found for both. 
Lastly, PDE4D8 expression did not show any association with DNA methylation (r = -0.233), 
agreeing with our observation that this isoform is not consistently expressed in prostate tissues 
(see Supplementary Figure 1). 
 
PDE4D isoforms can be used as diagnostic and prognostic signature for prostate cancer: 
application to prostate biopsies 
 
Since PDE4D7 and PDE4D5 show opposing behaviours in prostatic tissues, we created a 
diagnostic signature based on the expression of PDE4D7 relative to that of PDE4D5 
expression !"#4"7 − !"#4"5 . In order to evaluate its performance in distinguishing PCa 
and non-PCa samples, we carried out ROC analyses in all compatible datasets and compared 
the resulting AUCs with PCA3 (Supplementary Table 4). Overall, our diagnostic signature 
performed on par with PCA3, with AUCs ranging from 0.839 to 0.934 compared to 0.857 to 
0.921. 
In order to evaluate the value of PDE4D as a clinical biomarker, we used surgical resection 
materials of eighteen patients and subjected them to needle biopsies to obtain material from 
distinct areas, simulating both true positive and false negative biopsies (see Supplementary 
Table 5). In total, four biopsies with gradually increasing distance from the tumour were taken 
per patient (within tumour, edge of tumour, 5 mm from edge, and 10 mm from edge) and 
PDE4D5 as well as PDE4D7 expression were measured by qPCR. Ct values of both isoforms 
were normalized to several reference genes (see Methods) and adjusted to baseline expression 
in NAP tissue (10 mm from edge). Both expression profiles showed inverse correlation, with 
PDE4D5 expression decreasing in the vicinity of the tumour, while PDE4D7 expression as 
well as the diagnostic signature gradually increasing (see Figure 6), confirming our earlier 
findings. Additionally, a transient change of PDE4D isoform expression at the tumour edge 
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might suggest that nearby adjacent normal tissue is influenced by tumour presence through a 
‘field effect’, but could also be due to averaging signals from normal and cancerous cells. 
Notably, expression of all long PDE4D isoforms including PDE4D5 and PDE4D7 appears to 
decrease during PCa progression (see Figure 1 and Supplementary Figures 2-3), while 
expression of the super-short PDE4D isoforms PDE4D1 and PDE4D2 seemed to be affected 
to a lesser extent. On this basis, we decided to create a prognostic signature based on the 
expression level of PDE4D1/2 relative to the sum of the expression levels of the long 
PDE4D5, PDE4D7 and PDE4D9 isoforms (!"#4"1/2 − (!"#4"5 + !"#4"7 +!"#4"9)). The performance of this signature was then evaluated in the Exon Array cohorts. 
Since, three datasets had appropriate follow-up available, we used clinical recurrence (CR) 
defined as development of metastases after RP as clinical endpoint. Overall, our signature 
performed well in distinguishing patients with CR from those without, yielding AUCs of 
0.826, 0.794 and 0.614 for the EMC, Taylor and Erho cohort, respectively (Supplementary 
Table 4). Since the ‘EMC’ dataset offered time to biochemical recurrence (BCR), metastases-
free as well as overall survival time as follow-up information, we performed a Kaplan-Meier 
analysis for this dataset using our prognostic PDE4D signature. Two categories (signature 
high and low) were defined by Partitioning Around Medoids (PAM) and left-censoring was 
applied, resulting in well separated curves for both metastases-free and overall survival (p < 
0.05, see Figure 7). Subsequently, we used Cox proportional hazards regression model to 
evaluate whether our PDE4D signature is an independent predictor for clinical metastasis, 
BCR and overall survival, taking into account the pre-operational PSA, Gleason score, 
pathological stage, surgical margins and patient age. For both metastases-free as well as 
overall survival, the prognostic PDE4D signature was found to be an independent predictor (p 
< 0.1), though confidence intervals were large due to low numbers of samples and events 
(Supplementary Table 6). 
 
Discussion 
 
Our investigation of the transcriptional dynamics of the PDE4D gene locus revealed a 
previously undescribed promoter switch involving the major contributors of PDE4D activity 
in normal prostate, namely the PDE4D5 and PDE4D9 long forms, as well as the prostate 
cancer-associated long isoform PDE4D7 [15,16]. Unique promoters for each PDE4D isoform, 
located upstream of the exon(s) encoding their unique N-terminal regions allow for the 
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independent regulation of the different mRNA and corresponding protein expression [6,9,33]. 
Here in this study we provide the first evidence of condition-specific PDE4D promoter 
switching in a cancer context. 
Isoform switching in various genes (such as PKM, CXCR3 and FGR2 [34–36]) during cancer 
development has been described in several cancer types including prostate cancer [37–40], 
and likewise tumour-specific isoforms of known genes have been identified previously [41]. 
Indeed, the androgen receptor variant 7 (AR-V7) provides a particularly important example of 
a PCa-specific isoform that is constitutively active and ligand-independent, contributing to 
castration resistance of prostate cancer cells [42,43]. Furthermore, alternative promoter usage 
of the androgen-regulated gene TMPRSS2 as part of the TMPRSS2-ERG fusion gene also has 
been associated with clinical outcome [44,45]. 
Interestingly, mounting evidence suggests crosstalk between AR and cAMP signalling 
pathways, with important cAMP downstream targets such as PKA and ERK interacting either 
with the AR or AR target genes [4,46–48]. PDEs, in providing the sole route for degrading 
cAMP are poised to play a key regulatory role, particularly so as the targeting of particular 
isoforms to distinct signalling complexes confers a spatial aspect that allows particular 
isoforms to have specific functional roles [6]. Therefore, it is particularly intriguing to find 
that specific PDE4D isoforms expressed in prostatic tissues appear to be androgen regulated 
(PDE4D7 and PDE4D5), suggesting a complex network of interactions that links both 
pathways. We should, however, mention that studies of PDE4D7 expression in the VCaP 
prostate cancer cell line implied that it was not directly regulated by AR [15]. However, VCaP 
harbours genomic rearrangements on chr5q that are characteristic of chromothripsis, and more 
importantly, PDE4D is reportedly involved in gene fusions with FAM172A and C5orf47 [49]. 
With regards to the AR-induced up-regulation of PDE4D7 observed in LNCaP cells, these 
structural rearrangements in VCaP could be involved in a loss of AR-mediated regulation of 
PDE4D7 due to relocation or deletion of regulatory elements such as AR binding elements. 
An alternative explanation could be that PDE4D7 expression is indirectly linked to AR 
activity, as its promoter region overlaps PART1, a known AR target gene that showed clear 
association with androgen treatment in VCaP [15,50,51]. In the Exon Array datasets that we 
analysed, both genes seem to be co-expressed in prostatic tissues (mean Spearman’s rho = 
0.7269). However, given the fact that PDE4D5 was significantly down-regulated in LNCaP 
upon AR stimulation as well, we believe that AR directly influences PDE4D isoform 
expression through interaction with proximal or distal regulatory elements [52,53]. This 
hypothesis is supported by the ChIP-seq data for AR, which identifies numerous binding 
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peaks for AR in the PDE4D gene locus, including the PDE4D5 and PDE4D7/PART1 
promoter regions. 
Similarly, ERG seems to have a major contribution on PDE4D isoform expression, with us 
previously reporting that PDE4D7 is up-regulated in TMPRSS2-ERG positive PCa [16]. 
Here, we provided further ChIP-seq support for ERG involvement in PDE4D expression. 
However, the Exon Array datasets analysed here do not provide conclusive evidence for a link 
of ERG overexpression with other isoforms, such as PDE4D5. It appears therefore plausible 
that ERG overexpression may be specifically linked to PDE4D7 expression, highlighting a 
connection of the latter to the AR pathway, as well as its potential oncogenic role [15]. 
To investigate whether DNA methylation could be involved in the promoter switch uncovered 
in this study, we analysed three independent datasets based on different technologies, 
whereupon we discovered consistent increases of DNA methylation near the PDE4D5 TSS in 
PCa samples. In conjunction with the observed AR-mediated down-regulation of PDE4D5, 
these results could well explain the profound down-regulation of PDE4D5 in localized and 
advanced PCa and could hint at a protective function in normal prostate that is inhibited by 
gene silencing in PCa. In addition, we found increased DNA methylation near the PDE4D1/2 
TSS that could not be linked to significantly altered gene expression, while other isoforms 
showing differential methylation (PDE4D4, PDE4D8) do not seem to be consistently 
expressed in prostatic tissues. Indeed, it is even possible that the increased DNA methylation 
in the promoter regions of specific PDE4D isoforms might induce promoter switching to 
PDE4D7 by inhibiting expression of other PDE4D isoforms. 
Unlike PDE4D5, PDE4D9 does not show signs of androgen regulation despite being down-
regulated in PCa and we could not find evidence for DNA methylation-mediated regulation of 
PDE4D9 expression in PCa. Thus, its transcriptional regulation in PCa remains unclear at this 
point and solicits further study. 
Taken together, the observed switch in isoform usage might imply that regulatory 
mechanisms of PDE4D-catalyzed cAMP degradation are subjected to AR signalling in PCa 
cells that, in turn, indicates that PDE4D7-specific protein domains are necessary to regulate 
cAMP signalling in an androgen-dependent manner, offering a potentially new drug target 
[15,16,18]. Moreover, with the transition to an androgen-independent state, expression of long 
PDE4D isoforms seems to fade, reaching its minimum in castration-resistant conditions and 
distant metastases, while expression of the super-short isoforms PDE4D1 and PDE4D2 
appears to remain rather stable. Importantly, these super-short isoforms contain the catalytic 
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domain of PDE4D but lack the UCR1/UCR2 domains seen in long PDE4D isoforms, a 
module that confers regulation by various kinases and influences intracellular targeting [6,18].  
Hence, this effective loss of regulation of PDE4D activity can be expected to generate 
profound changes in compartmentalized cAMP signaling due to altered spatial localization 
and cross-talk governing cAMP degradation, and may thereby contribute to cancer 
aggressiveness similarly to mechanisms suggested for MAPKs [54] and AR in form of its 
splice variant AR-V7 [43].  
PDE4D isoform composition appears to have merit in being used as a diagnostic signature 
following the expression of PDE4D7 and PDE4D5, as well as serving as a prognostic 
signature following the difference between the expression of long and short PDE4D isoforms. 
Evaluating both signatures, we found that they exhibited good performance in distinguishing 
PCa from normal tissue and progressive from non-progressive samples, respectively. 
Importantly, diagnostic performance was robust to differences in technology, data processing, 
as well as potential differences in composition and patient characteristics of the used cohorts, 
demonstrating a high cross-platform reproducibility of PDE4D isoforms as PCa biomarker 
and yielding results comparable to the established PCa-marker PCA3 in all tested cohorts. 
Hence, with further optimization to an appropriate test platform prior to clinical utilization, 
we could imagine that such signatures might provide a valuable addition to complement 
existing test procedures. 
When applying our diagnostic signature to prostate biopsies, PDE4D isoform expression 
appeared to return to its ‘normal’ state with increasing distance from the tumour, whereas the 
tumour edge showed an intermediate signal. This observation could hint at a ‘field effect’ of 
the tumour on and/or crosstalk of the tumour cells with the surrounding microenvironment 
[55–58]. It would therefore be fascinating to further explore in the future whether such a ‘field 
effect’ indeed influences PDE4D isoform composition, effectively increasing the target area 
for biopsies, or whether our observations were caused by averaging signals from adjacent 
tumour and normal cells. If validated, an increased target area could boost accuracy of 
prostate biopsies, reducing the number of false negative tests. Furthermore, it would be highly 
interesting to see whether reversing the isoform composition to its normal state has an 
influence on prostate cell phenotype and behaviour. 
 
While our study focused on PDE4D isoform expression in primary PCa samples, genomic 
alterations of the PDE4D locus such as microdeletions have been observed in other cancers 
[27]. Moreover, a recent study found that mutations in other members of the PDE family 
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could be related to PCa by affecting intracellular cAMP and/or cGMP levels [59]. 
Considering the large number of PDE genes and isoforms as well as the tight regulation of 
cAMP signalling and its degradation, it is very well possible that PDEs such as PDE4D are 
key players in other conditions, as the broad panel of associated diseases underscores [10–14]. 
Therefore, it is worthwhile to extend the presented study and screen the expression profiles of 
all known PDEs in various tissues and conditions to define basal expression levels and reveal 
potential alterations and novel targets for drug interventions. 
Taken together, our findings highlight the potential of PDE4D isoforms to be promising new 
biomarkers and potential therapeutic targets for localized and advanced prostate cancer. 
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Materials and Methods 
 
Analysis of PDE4D isoform expression in prostate tissues 
 
Quantification of PDE4D isoforms in patient materials was performed by qRT-PCR as 
described in [16]. In addition, six independent Exon Array datasets were used in this study 
and raw CEL files were obtained via Gene Expression Omnibus (GEO) or personal 
communication. The datasets comprised GSE21034 [25], GSE29079 [30], GSE46691 [60], 
GSE32875 [28] as well as patient samples from GSE41410 [61,62] and samples published in 
[63]. These datasets are referred to as 'Taylor', 'Brase', 'Erho', 'Rajan', 'EMC', and 'Nijmegen', 
respectively. 
Of note, patients PCA0041, PCA0042 and PCA0119 of the Taylor dataset were marked as 
‘treated with salvage radical prostatectomy (RP)’, meaning they previously failed 
radiotherapy treatment and were subsequently treated with RP. Therefore, Exon Array 
expression data for PCA0119 were not used for survival analysis. 
Raw data were processed and RMA normalized using the aroma.affymetrix R-package ([64], 
CDF used: HuEx-1_0-stv2,extendedR3,A20071112,EP.CDF, see http://www.aroma-
project.org/). Expression of transcript isoforms was measured by using log2-transformed 
intensity values of isoform-specific probesets: PDE4D1/2 (2858166); PDE4D3 (2858290, 
2858291); PDE4D4 (2858368, 2858369, 2858370); PDE4D5 (2858345, 2858346, 2858347); 
PDE4D6 (2858155, 2858156); PDE4D7 (2858406, 2858407, 2858408); PDE4D8 (2858257, 
2858258); PDE4D9 (2858240, 2858241). These intensity values were normalized to a set of 
reference genes (HPRT1, PUM1, TBP, POLR2A, TUBA1B) by using the mean intensity of 
‘core’ probesets of each gene’s transcript cluster (3991698, 2404254, 2937984, 3453732, 
3708704) to estimate gene expression and then using the average reference gene expression as 
normalization factor. This normalization factor was subtracted from the probeset intensity 
values, and normalized probeset expression was subsequently averaged per PDE4D isoform. 
In addition, expression of the PCa associated genes was normalized the same way as PDE4D, 
using ‘core’ and ‘extended’ probesets of transcript cluster 3175538 to measure PCA3 as well 
as 3931765 for ERG and 2811145 for PART1. 
Lastly, level 3 processed RNA-seq expression values for PRAD samples were obtained from 
TCGA (https://tcga-data.nci.nih.gov/tcga/) via the TCGA-Assembler R-package [65]. For 
each samples, the RSEM 'scaled estimate' values were used and multiplied by 106 to convert 
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the values to transcripts per million (TPM). Error bars in plots represent standard deviation 
unless stated otherwise. 
 
Analysis of deletions of PDE4D and impact on isoform expression 
 
Gene-level copy number alterations were obtained from TCGA via the TCGA-Assembler R-
package [65] and a cut-off of ±log2(1.5/2) was used to call gains and losses of genetic 
material, respectively. A Wilcoxon-Mann-Whitney test was used to identify significant 
changes in expression of PDE4D isoforms between samples with and without alterations. 
 
Evaluation of AR and ERG expression / binding on PDE4D transcription 
 
To determine the (TMPRSS2-)ERG status of patient samples in Exon Array cohorts, we used 
relative ERG expression values and applied Partitioning Around Medoids (PAM, R-package 
'cluster', k = 2) to assign the patient samples to the ERG positive or negative group based on 
expression. Lastly, a Wilcoxon-Mann-Whitney-test was used to detect statistically significant 
differences (p < 0.05) between the ERG positive and ERG negative samples. Likewise, 
differences between R1881 treated and untreated LNCaP cells [28] were tested using a 
Wilcoxon-Mann-Whitney-test. To investigate transcription factor binding, public ChIP-seq 
peaks for AR and ERG were obtained from GEO (GSE14092) and overlapped with PDE4D 
TSS ± 2 kb regions using bedtools [66] after conversion to hg19 coordinates using the 
liftOver executable (https://genome.ucsc.edu/cgi-bin/hgLiftOver). Distances of the nearest 
AR and ERG peaks to each PDE4D isoform TSS were calculated by 'bedtools closest' using 
the options '-k 5 and -d'. Data visualization was based on the ggBio R-package [67]. 
Enrichment of AR and ERG peaks in the PDE4D gene locus was investigated by counting the 
number of ChIP-seq peaks of each transcription factor within 21,209 RefSeq gene loci (hg19) 
as well as randomly sampled genomic regions of 1.5 Mb. Unique gene loci were defined by 
the minimum and maximum chromosomal coordinates of RefSeq NM and NR transcripts 
belonging to the same gene identifier after associating them to HGNC gene symbols using 
biomaRt [68] and excluding minor chromosomes and haplotypes. For each chromosome, 
random regions were sampled according to: /01234	67	43896/: =	(chromosome	size	in	Mb	 ∗ 	1000)  and any regions overlapping the PDE4D gene locus 
were excluded. Counting was performed by bedtools [66] annotate using the option '-counts' 
and empirical cumulative distribution functions for both transcription factors were created by 
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using the ecdf() function of R-package stats. Hexbinplots were generated using the 
BoutrosLab.plotting.general R-package (http://labs.oicr.on.ca/boutros-lab/software/bpg). 
 
Investigation of PDE4D promoter methylation 
 
Public methylation data were downloaded from GEO and TCGA data portal and comprised 
three different technologies. 1) Deduplicated and extended MeDIP-seq reads (200 nt) 
deposited under accession number GSE35342 [31] were downloaded from Gene Expression 
Omnibus (GEO) and processed via the MEDIPS R-package [69]. Using genomic bins of 100 
nt for chromosome 5, reads were counted for every sample and differential methylation status 
of each bin was tested using the following MEDIPS settings as suggested by the authors upon 
request: 'diff.method = "edgeR", prob.method = "poisson", MeDIP = F, CNV = F'. Bins 
covering the genomic region of PDE4D including 50 kb flanks and with a Bonferroni-
adjusted p-value below 0.01 were selected and merged into larger regions of interest (ROIs) if 
they were directly adjacent. 2) Pre-processed public bisulfite sequencing (BiS-seq) data 
available from GEO (GSE41701, [70]) were downloaded, and measured positions found in 
the genomic region of PDE4D including 50 kb flanks were extracted. For each position, the 
percentage of reads indicating methylation was calculated by #base calls C / (#base calls C + 
#base calls T) based on the number of reads covering a particular base. Next, the limma R-
package [71,72] was used to identify positions with significant differences in methylation 
between PCa vs. benign, as well as CRPC vs. PCa. Positions with FDR < 0.05 were selected 
and merged into larger regions if they were within 100 nts of each other. 3) TCGA level 3 
data for Illumina Infinium HumanMethylation450 BeadChips were downloaded from TCGA 
data portal and only patients with available clinical information were used for further analysis. 
Pre-calculated beta values for chromosome 5 were imported into Minfi [73] and annotated 
using 'ilmn12.hg19'. Analysis of differential methylation was performed via bumphunter 
using 100 permutations and 'cutoff=0.15'. Lastly, any significant probes located within the 
genomic region of PDE4D including 50 kb flanks were extracted and methylation profiles 
were correlated to RNA expression via Spearman’s correlation coefficient. Visualisation of 
methylated regions was performed using ggBio [67]. 
 
Analysis of signature performance, survival and independent predictor variable 
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We created a diagnostic signature based on PDE4D7 expression relative to PDE4D5 
expression (PDE4D7-PDE4D5) as well as a prognostic signature for the Exon Array cohorts 
based on PDE4D1/2 relative to PDE4D5, PDE4D7 and PDE4D9 ((PDE4D1/2) - 
(PDE4D5+PDE4D7+PDE4D9)). Subsequently, the R-packages ‘ROC’ and ‘survival’ were 
used to carry out ROC analyses and perform a Cox regression as well as Kaplan-Meier 
analysis based on available survival data of the EMC dataset [61,62]. 
 
Quantification of diagnostic PDE4D signature in prostate biopsies 
 
Several biopsy punches (approximately 1 x 2 mm) were taken in a representative tumour area 
after surgical prostate resections in eighteen different men with prostate cancer. Experimental 
protocols were approved by the Erasmus MC Medical Ethics Committee following the 
Medical Research Involving Human Subjects Act. For each patient, these punches were 
performed within the tumour, at the edge of the tumour area, at 5 and at 10 mm distance to the 
tumour region. RNA was extracted and qRT-PCRs (quantitative real-time PCR) for PDE4D5 
and PDE4D7 were performed as described in [16], using ACTB, HPRT1, TUBA1B, 
POLR2A, PUM1 and TBP as reference genes. The expression of PDE4D5 and PDE4D7 in 
each biopsy tissue was normalized as follows: mean(Ct(reference genes)) – Ct(PDE4DX). For 
each of the eighteen different patients, the normalized expression of PDE4D transcripts within 
the tumour was set to 1 and expression values for biopsies taken at various distances from the 
tumour were calculated relative to the expression in the tumour. Lastly, average relative 
expression and standard error of the mean of PDE4D transcript expression were plotted for 
each of the respective biopsy locations. 
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Figure legends 
Figure 1: Overview of PDE4D isoform expression in prostatic tissues. Normalized 
PDE4D isoform expression in the ‘EMC’ dataset across different prostate conditions. CR – 
clinical recurrence, BCR – biochemical recurrence, CPRC – castration resistant prostate 
cancer. Significant differences (p < 0.05, Wilcoxon-Mann-Whitney test) are indicated with *. 
Figure 2: Relation of copy number events and PDE4D expression in the TCGA cohort. 
32 normal adjacent prostate samples are compared to PCa samples with (n=12) and without 
(n=171) loss of genetic material in the PDE4D locus to investigate whether decreased 
expression occurs independently of PDE4D deletions. Significant differences in expression 
are denoted with * (p < 0.05, Wilcoxon-Mann-Whitney test). 
Figure 3: Investigating potential ERG regulation of PDE4D isoforms. Since only 
PDE4D7 has been previously reported as up-regulated in ERG positive PCa samples [16], 
expression of PDE4D1/2, PDE4D5, PDE4D7 and PDE4D9 was tested in ERG negative and 
ERG positive samples across five Exon Array datasets (* = p < 0.05, ** = p < 0.001, 
Wilcoxon-Mann-Whitney test). 
Figure 4: Investigation of androgen receptor involvement in PDE4D expression. 
Expression of PDE4D isoforms in LNCaP cells with or without addition of the synthetic 
androgen R1881 [28]. 
Figure 5: AR and ERG binding peaks in PDE4D in the VCaP cell line. To visualize AR 
and ERG binding in PDE4D, genomic locations of ChIP-seq peaks (GSE14092) denoting AR 
binding sites are coloured blue, while ERG peaks are coloured in red. If peaks of both 
transcription factors overlap, the affected genomic regions are coloured in black. A genomic 
region surrounding each transcription start site (TSS) is used to highlight binding events that 
could influence transcription. 
Figure 6: Applying the diagnostic PDE4D signature in needle biopsies. Expression of 
PDE4D5 and PDE4D7 in relation to distance to the tumour as measured by qRT-PCR in 
prostate tumour biopsies (n = 18). Error bars represent standard error of the mean. 
Figure 7: Survival analysis for prognostic PDE4D signature. Using the prognostic PDE4D 
signature to distinguish between outcomes, Kaplan Meier curves for three clinical endpoints 
were created based on the ‘EMC’ dataset. Assignment of samples to the high and low 
signature group was performed by clustering of samples according to their signature values 
using Partitioning Around Medoids (PAM). 
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